{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T04:42:28Z","timestamp":1785300148775,"version":"3.55.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"vor","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s00277-025-06295-0","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T20:14:57Z","timestamp":1741810497000},"page":"1655-1667","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Anti-CD20 maintenance strategies to face the challenge of COVID-19 pandemic in follicular lymphoma: results from the R-FolSTOP multicentre Italian study"],"prefix":"10.1007","volume":"104","author":[{"given":"Alessia","family":"Castellino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Comba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Bertolotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carola","family":"Boccomini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Clerico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Nicoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Vanazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fulvia","family":"Fanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommasina","family":"Perrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Marchesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Cocito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Merli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Bigliardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Mecacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Bozzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Margiotta-Casaluci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Meli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Anastasia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Farina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ombretta","family":"Annibali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annarita","family":"Conconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Rattotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Galimberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Castellino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Massaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,12]]},"reference":[{"issue":"3","key":"6295_CR1","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1002\/ajh.25696","volume":"95","author":"A Freedman","year":"2020","unstructured":"Freedman A, Jacobsen E (2020) Follicular lymphoma: 2020 update on diagnosis and management. Am J Hematol 95(3):316\u2013327","journal-title":"Am J Hematol"},{"issue":"31","key":"6295_CR2","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1200\/JCO.19.01073","volume":"37","author":"E Bachy","year":"2019","unstructured":"Bachy E, Seymour JF, Feugier P, Offner F, L\u00f3pez-Guillermo A, Belada D et al (2019) Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study. J Clin Oncol 37(31):2815\u20132824","journal-title":"J Clin Oncol"},{"issue":"9759","key":"6295_CR3","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","volume":"377","author":"G Salles","year":"2011","unstructured":"Salles G, Seymour JF, Offner F, L\u00f3pez-Guillermo A, Belada D, Xerri L et al (2011) Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 377(9759):42\u201351","journal-title":"Lancet"},{"issue":"27","key":"6295_CR4","doi-asserted-by":"publisher","first-page":"3351","DOI":"10.1200\/JCO.2012.44.8290","volume":"31","author":"U Vitolo","year":"2013","unstructured":"Vitolo U, Ladetto M, Boccomini C, Baldini L, De Angelis F, Tucci A et al (2013) Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana Linfomi. J Clin Oncol 31(27):3351\u20133359","journal-title":"J Clin Oncol"},{"issue":"4","key":"6295_CR5","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/bjh.15720","volume":"184","author":"BT Hill","year":"2019","unstructured":"Hill BT, Nastoupil L, Winter AM, Becnel MR, Cerhan JR, Habermann TM et al (2019) Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma. Br J Haematol 184(4):524\u2013535","journal-title":"Br J Haematol"},{"issue":"23","key":"6295_CR6","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1200\/JCO.2017.76.8960","volume":"36","author":"W Hiddemann","year":"2018","unstructured":"Hiddemann W, Barbui AM, Canales MA, Cannell PK, Collins GP, D\u00fcrig J et al (2018) Immunochemotherapy With obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: Influence of chemotherapy on efficacy and safety. J Clin Oncol 36(23):2395\u20132404","journal-title":"J Clin Oncol"},{"issue":"11","key":"6295_CR7","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1182\/blood-2013-04-494096","volume":"122","author":"I Nazi","year":"2013","unstructured":"Nazi I, Kelton JG, Larch\u00e9 M, Snider DP, Heddle NM, Crowther MA et al (2013) The effect of rituximab on vaccine responses in patients with immune thrombocytopenia. Blood 122(11):1946\u20131953","journal-title":"Blood"},{"issue":"11","key":"6295_CR8","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.clml.2020.08.017","volume":"20","author":"H Yasuda","year":"2020","unstructured":"Yasuda H, Tsukune Y, Watanabe N, Sugimoto K, Uchimura A, Tateyama M et al (2020) Persistent COVID-19 pneumonia and failure to develop anti-SARS-CoV-2 antibodies during rituximab maintenance therapy for Follicular Lymphoma. Clin Lymphoma Myeloma Leuk 20(11):774\u2013776","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"6295_CR9","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.clml.2020.06.012","volume":"21","author":"Z Wright","year":"2021","unstructured":"Wright Z, Bersabe A, Eden R, Bradley J, Cap A (2021) Successful use of COVID-19 convalescent plasma in a patient recently treated for Follicular Lymphoma. Clin Lymphoma Myeloma Leuk 21(1):66\u201368","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"6295_CR10","doi-asserted-by":"publisher","first-page":"e279","DOI":"10.1111\/bjh.16935","volume":"190","author":"V Shah","year":"2020","unstructured":"Shah V, Ko Ko T, Zuckerman M, Vidler J, Sharif S, Mehra V et al (2020) Poor outcome and prolonged persistence of SARS-CoV-2 RNA in COVID-19 patients with haematological malignancies; King\u2019s College Hospital experience. Br J Haematol 190(5):e279\u2013e282","journal-title":"Br J Haematol"},{"issue":"103358","key":"6295_CR11","first-page":"5","volume":"57","author":"I Schiavetti","year":"2022","unstructured":"Schiavetti I, Ponzano M, Signori A, Bovis F, Carmisciano L, Sormani MP (2022) Severe outcomes of COVID-19 among patients with multiple sclerosis under anti-CD-20 therapies: A systematic review and meta-analysis. Mult Scler Relat Disord 57(103358):5","journal-title":"Mult Scler Relat Disord"},{"key":"6295_CR12","first-page":"9388813","volume":"21","author":"M Barzegar","year":"2022","unstructured":"Barzegar M, Houshi S, Sadeghi E, Hashemi MS, Pishgahi G, Bagherieh S et al (2022) Association of disease-modifying therapies with COVID-19 susceptibility and severity in patients with multiple sclerosis: a systematic review and network meta-analysis. Mult Scler Int 21:9388813","journal-title":"Mult Scler Int"},{"issue":"12","key":"6295_CR13","doi-asserted-by":"publisher","first-page":"e807","DOI":"10.1097\/HS9.0000000000000807","volume":"6","author":"D Galusic","year":"2022","unstructured":"Galusic D, Basic-Kinda S, Pijuk A, Milunovic V, Dreta B, Franjic N et al (2022) Efficacy and safety of obinutuzumab-chemotherapy combinations in front-line treatment of follicular non-hodgkin lymphoma during the COVID-19 pandemic: A Study of KROHEM, the croatian cooperative group for hematologic diseases. Hemasphere 6(12):e807","journal-title":"Hemasphere"},{"issue":"1","key":"6295_CR14","first-page":"173","volume":"110","author":"\u00c1 Serna","year":"2025","unstructured":"Serna \u00c1, Navarro V, Iacoboni G, L\u00f3pez L, Sancho JM, Gonz\u00e1lez-Barca E et al (2025) Rituximab maintenance after bendamustine-based treatment for follicular lymphoma and mantle cell lymphoma may exert a negative influence on SARS-CoV-2 infection outcomes. Haematologica 110(1):173\u2013178","journal-title":"Haematologica"},{"key":"6295_CR15","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1111\/bjh.19661","volume":"205","author":"A Pinto","year":"2024","unstructured":"Pinto A, Caltagirone M, Battista M, Gazzoli GC, Patti C, Pennese E et al (2024) Exposure to obinutuzumab does not affect outcomes of SARS-CoV-2 infection in vaccinated patients with newly diagnosed\u00a0advanced-stage follicular lymphoma. Br J Haematol. 205:2219\u20132219","journal-title":"Br J Haematol."},{"issue":"3","key":"6295_CR16","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1111\/bjh.19166","volume":"204","author":"IY Gong","year":"2024","unstructured":"Gong IY, Prica A, Ante Z, Calzavara A, Krzyzanowska MK, Singh S et al (2024) Indolent lymphoma care delivery and outcomes during the COVID-19 pandemic in Ontario. Canada Br J Haematol 204(3):805\u2013814","journal-title":"Canada Br J Haematol"},{"issue":"10","key":"6295_CR17","doi-asserted-by":"publisher","first-page":"e737","DOI":"10.1016\/S2352-3026(20)30251-9","volume":"7","author":"F Passamonti","year":"2020","unstructured":"Passamonti F, Cattaneo C, Arcaini L, Bruna R, Cavo M, Merli F et al (2020) Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol 7(10):e737\u2013e745","journal-title":"Lancet Haematol"},{"key":"6295_CR18","doi-asserted-by":"publisher","first-page":"693","DOI":"10.3390\/v15030693","volume":"15","author":"E \u0141y\u017cwa","year":"2023","unstructured":"\u0141y\u017cwa E, Sobiecka M, Lewandowska K, Siemion-Szcze\u015bniak I, Bara\u0144ska I, Klatt M et al (2023) Prolonged SARS-CoV-2 Infection and Organizing Pneumonia in a Patient with Follicular Lymphoma, Treated with Obinutuzumab-Challenging Recognition and Treatment. Viruses. 15:693 (Switzerland)","journal-title":"Viruses."},{"key":"6295_CR19","doi-asserted-by":"publisher","first-page":"106973","DOI":"10.1016\/j.ijid.2024.02.016","volume":"141","author":"L Huang","year":"2024","unstructured":"Huang L, Tong X, Cui J, Du X, Liao Y, Tan X et al (2024) Recurrent and persistent fever after SARS-CoV-2 infection in patients with follicular lymphoma: A case series. Int J Infect Dis 141:106973","journal-title":"Int J Infect Dis"},{"issue":"4","key":"6295_CR20","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1159\/000521121","volume":"145","author":"P Mart\u00ednez-Barranco","year":"2022","unstructured":"Mart\u00ednez-Barranco P, Garc\u00eda-Roa M, Trelles-Mart\u00ednez R, Arribalzaga K, Velasco M, Guijarro C et al (2022) Management of persistent SARS-CoV-2 infection in patients with follicular Lymphoma. Acta Haematol 145(4):384\u2013393","journal-title":"Acta Haematol"},{"issue":"1","key":"6295_CR21","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1186\/s12879-024-09631-3","volume":"24","author":"S Maruyama","year":"2024","unstructured":"Maruyama S, Wada D, Kanayama S, Shimazu H, Miyano Y, Inoue A et al (2024) The evaluation of risk factors for prolonged viral shedding during anti-SARS-CoV-2 monoclonal antibodies and long-term administration of antivirals in COVID-19 patients with B-cell lymphoma treated by anti-CD20 antibody. BMC Infect Dis 24(1):715","journal-title":"BMC Infect Dis"},{"issue":"7","key":"6295_CR22","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1200\/JCO.21.01234","volume":"40","author":"S Luminari","year":"2022","unstructured":"Luminari S, Manni M, Galimberti S, Versari A, Tucci A, Boccomini C et al (2022) Response-adapted postinduction strategy in patients with advanced-stage Follicular Lymphoma: The FOLL12 study. J Clin Oncol 40(7):729\u2013739","journal-title":"J Clin Oncol"},{"issue":"13","key":"6295_CR23","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1002\/cncr.34221","volume":"128","author":"A Rajam\u00e4ki","year":"2022","unstructured":"Rajam\u00e4ki A, Hujo M, Sund R, Prusila REI, Kuusisto MEL, Kuitunen H et al (2022) Mortality among patients with low-grade follicular lymphoma: A binational retrospective analysis. Cancer 128(13):2474\u20132482","journal-title":"Cancer"},{"issue":"2","key":"6295_CR24","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/bjh.19562","volume":"205","author":"YJ Lim","year":"2024","unstructured":"Lim YJ, Ward V, Brown A, Phillips E, Kronsteiner B, Malone T et al (2024) Immunogenicity of COVID-19 vaccines in patients with follicular lymphoma receiving frontline chemoimmunotherapy. Br J Haematol 205(2):440\u2013451","journal-title":"Br J Haematol"},{"issue":"1","key":"6295_CR25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/infdis\/jiae106","volume":"230","author":"EA Chong","year":"2024","unstructured":"Chong EA, Kumashie KG, Chong ER, Fabrizio J, Gupta A, Svoboda J et al (2024) Immunologic predictors of vaccine responsiveness in patients with lymphoma and chronic lymphocytic leukemia. J Infect Dis 230(1):15\u201327","journal-title":"J Infect Dis"},{"issue":"9","key":"6295_CR26","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1038\/s41375-024-02336-1","volume":"38","author":"AM Spanjaart","year":"2024","unstructured":"Spanjaart AM, Ljungman P, Tridello G, Schwartz J, Martinez-Cibri\u00e1n N, Barba P et al (2024) Improved outcome of COVID-19 over time in patients treated with CAR T-cell therapy: Update of the European COVID-19 multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party (IDWP) and the European Hematology Association (EHA) Lymphoma Group. Leukemia 38(9):1985\u20131991","journal-title":"Leukemia"},{"issue":"16","key":"6295_CR27","first-page":"suppl.70","volume":"42","author":"LA Lori","year":"2024","unstructured":"Lori LA, Falchi L, Vermaat JSP (2024) Epcoritamab with rituximab + lenalidomide (R2) in previously untreated (1L) follicular lymphoma (FL) and epcoritamab maintenance in FL: EPCORE NHL-2 arms 6 and 7. J Clin Oncol 42(16):suppl.70","journal-title":"J Clin Oncol"}],"updated-by":[{"DOI":"10.1007\/s00277-025-06369-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000}}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06295-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06295-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06295-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T05:56:09Z","timestamp":1745646969000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06295-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["6295"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06295-0","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00277-025-06369-z","asserted-by":"object"}]},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"28 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00277-025-06369-z","URL":"https:\/\/doi.org\/10.1007\/s00277-025-06369-z","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}